Immunome gains 28% pre-market as varegacestat trial meets primary endpoint

Monday, Dec 15, 2025 7:05 am ET1min read

Immunome gains 28% pre-market as varegacestat trial meets primary endpoint

Comments



Add a public comment...
No comments

No comments yet